Abstracts tagged "Vasculitis"

Abstract Number: 2532 • ACR Convergence 2025
Temporal arteritis revealing eosinophilic diseases: A multicenter retrospective study, literature review, and combined cluster analysis
Julie Merindol¹, Benjamin Torreau², Matthieu Groh³, Amy Klion⁴, Paolo Delvino⁵, Olivier Espitia⁶, Jean-Benoit Arlet⁷, Sarah Lechtman⁸, Jean-sébastien Allain⁹, Federica Bello¹⁰, Anaelle Boucaud¹¹, Florian Catros¹², Julien Campagne¹³, Anne Coutard¹⁴, Cecile-Audrey DUREL¹⁵, Mikael Ebbo¹⁶, Georgina Espigol-Frigole¹⁷, Giacomo Emmi¹⁸, Yanis Kouchit¹⁹, Guillaume Lefevre²⁰, François Lifermann²¹, PAUL LEGENDRE²², Eric Liozon²³, Francois Maurier²⁴, Sara Melboucy Belhkir²⁵, Sébastien Miranda²⁶, Simon Parreau²³, Paola Parronchi²⁷, Jacques Pouchot²⁸, Vincent Pestre²⁹, Sophie Rosenstingl³⁰, Jan Willem Cohen Tervaert³¹, Odile Souchaud Debouverie³², Xavier Puéchal³³ and Benjamin Terrier³⁴, ¹CHU de Nice, Nice, France, ²Internal Medicine and Immunology, CHU Tours, Tours, France, ³Hôpital Foch, paris, France, ⁴NIAID/NIH, Bethesda, MD, ⁵University of Milano-Bicocca, Monza, Monza and Brianza, Italy, ⁶CHU de Nantes, Nantes, France, ⁷APHP, Paris, ⁸CHU de Nice, Nixe, France, ⁹Scorff-Lorient Hospital, Lorient, France, ¹⁰Université de Florence, Florence, Italy, ¹¹CHU de Tours, Tours, France, ¹²CHI VAL, Ariège, France, ¹³Hopital Robert Schuman, Metz, France, ¹⁴Groupe Hospitalier de Bretagne Sud, Lorient, France, ¹⁵CHU de Lyon, Lyon, France, ¹⁶Internal Medicine, Marseille-APHM, hôpital La Timone, Marseille, France, ¹⁷Hospital Clínic de Barcelona, Barcelona, Spain, ¹⁸Department of Medical, Surgery and Health Sciences, University of Trieste, Italy and Clinical Medicine and Rheumatology Unit, Cattinara University Hospital, Trieste, Italy, Trieste, Italy, ¹⁹CH de Cannes, Cannes, France, ²⁰CHU de Lille, Lille, France, ²¹Internal Medicine, CH de Dax, Dax, France, ²²CH LE MANS, Le Mans, France, ²³CHU de Limoges, Limoges, France, ²⁴HOPITAUX PRIVES DE METZ, Vaux / Frankreich, France, ²⁵CH de Saint Quentin, Saint Quentin, France, ²⁶Internal Medicine, CHU Rouen, Rouen, France, ²⁷CHU de Florence, Florence, Italy, ²⁸AP-HP, Rueil Malmaison, France, ²⁹CH d'Avignon, Avignon, France, ³⁰CH de Compiegne, Compiegne, France, ³¹University of Alberta, Edmonton, AB, Canada, ³²CHU de Poitiers, Poitiers, France, ³³Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, and Université Paris Cité, Paris ( ⁷⁵⁰¹⁴ ), Ile-de-France, France, ³⁴Cochin Hospital, Paris, France
Background/Purpose: Temporal arteritis (TA) classically presents as a large-vessel vasculitis in older adults with cranial ischemic symptoms. However, in younger patients or in the presence…
Abstract Number: 1765 • ACR Convergence 2025
Maintenance of remission with rituximab versus azathioprine in newly diagnosed or relapsing eosinophilic granulomatosis with polyangiitis. A prospective, randomized, controlled, double-blind trial
Xavier Puéchal¹, Grégory Pugnet², Elisabeth Diot³, Claire de Moreuil⁴, Stéphane Jouneau⁵, Thomas Quemeneur⁶, Gabriel Baron⁷, Perrine Smets⁸, Antoine Néel⁹, Thomas Le Gallou¹⁰, Nicolas Noël¹¹, Yurdagül Uzunhan¹², Cloé Comarmond¹³, Geoffrey Urbanski¹⁴, Ygal Benhamou¹⁵, Alice Bérezné¹⁶, Arsène Mekinian¹⁷, Mohamed Hamidou⁹, Julien Campagne¹⁸, Noemie Abisror¹⁹, Benjamin Torreau³, Pascal Cohen²⁰, Loic Guillevin²⁰, Philippe Ravaud⁷ and Benjamin Terrier²¹, ¹Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, and Université Paris Cité, Paris ( ⁷⁵⁰¹⁴ ), Ile-de-France, France, ²CHU Toulouse Rangueil Service de Medecine Interne et Immunologie Clinique, Toulouse, France, ³Internal Medicine and Immunology, CHU Tours, Tours, France, ⁴CHU DE BREST, BREST, France, ⁵Respiratory Medicine, Université de Rennes ¹, CHU Pontchaillou, Rennes, France, ⁶Nephrology and Internal Medicine, CH Valenciennes, Valenciennes, France, ⁷Hôtel-Dieu, Université Paris Cité,, Paris, France, ⁸Internal Medicine, CHU Gabriel-Montpied, Clermont-Ferrand, France, ⁹Internal Medicine, CHU Hôtel-Dieu, Nantes, France, ¹⁰Internal Medicine and Clinical Immunology, CHU Rennes Sud, Rennes, ¹¹Internal Medicine and Clinical Immunology, CHU Bicêtre, Bicêtre, ¹²Respiratory Medicine, Hôpital Avicenne, Bobigny, France, ¹³Department of Internal Medicine, Lariboisière University Hospital, Université Paris Cité, Assistance Publique Hôpitaux de Paris, INSERM U⁹⁴², Paris, France, ¹⁴Internal Medicine and Clinical Immunology, CHU Angers, Angers, France, ¹⁵Internal Medicine, CHU Rouen, Rouen, France, ¹⁶Internal Medicine, CH, Annecy, Annecy, France, ¹⁷Department of Internal Medicine, Inflammation-Immunopathology-Biotherapy Department (DMU i³), Saint-Antoine University Hospital, ⁷⁵⁰¹² Paris, France, Paris, France, ¹⁸Internal Medicine, CH Robert Schuman, Metz, France, ¹⁹Internal Medicine, CHU Saint-Antoine,, Paris, France, ²⁰Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, Paris, France, ²¹Cochin Hospital, Paris, France
Background/Purpose: The eosinophilic granulomatosis with polyangiitis (EGPA) guidelines recommend considering maintenance therapy after remission to reduce the risk of relapse and toxicity, but data on…
Abstract Number: 1605 • ACR Convergence 2025
Combined Anti-IL-5/IL-5R and Dupilumab Therapy in Eosinophilic Granulomatosis with Polyangiitis: A European Retrospective Study
Miriam Guerini¹, Pavel Novikov², Roberto Padoan³, Georgina Espigol-Frigole⁴, Jan Willem Cohen Tervaert⁵, Vincent Grobost⁶, Laurent Guilleminault⁷, Jan Walter Schroeder⁸, Bernhard Hellmich⁹, Joana Martins-Martinho¹⁰, Camillo Ribi¹¹, Mathieu Groh¹² and Benjamin Terrier¹³, ¹IRCCS Policlinico S. Matteo, University of Pavia, Pavia, Italy, ²Sechenov University, Moscow, Russia, ³University of Padova, Padova, Italy, ⁴Hospital Clínic de Barcelona, Barcelona, Spain, ⁵University of Alberta, Edmonton, AB, Canada, ⁶Internal medicine, CHU Clermont Ferrand Estaing, Clermont Ferrand, France, ⁷CHU Toulouse, Toulouse University, Toulouse, France, ⁸ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy, ⁹Klinik für Innere Medizin, Rheumatologie und Immunologie, medius Klinik Kirchheim, Kirchheim unter Teck, Germany, ¹⁰ULS Santa Maria, Lisbon, Portugal, ¹¹Lausanne University Hospital / University of Lausanne, Lausanne, Switzerland, ¹²Hôpital Foch, Suresnes, France, ¹³Cochin Hospital, Paris, France
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a small-vessel vasculitis characterized by asthma, ear, nose, and throat (ENT) symptoms, eosinophilia, and systemic involvement. Despite the…
Abstract Number: 0714 • ACR Convergence 2025
Factors Associated With Depression And Anxiety In ANCA-Associated Vasculitis Patients: Data From The Almenara Vasculitis Cohort
Alvaro Oyarce-Calderón¹, Allison Figueroa-Sánchez², Leonor León-Yaurimucha², Rocío Gamboa-Cárdenas³, Zoila Rodríguez-Bellido⁴, Risto Perich-Campos⁵, Graciela Alarcón⁶, Manuel Ugarte-Gil⁷ and Victor Pimentel-Quiroz⁸, ¹Hospital Nacional Guillermo Almenara Irigoyen, San Miguel, Lima, Peru, ²Universidad Científica del Sur, Lima, Peru, ³Universidad Científica del Sur, Lima, Peru, ⁴Hospital Nacional Guillermo Almenara Irigoyen; Universidad Nacional Mayor de San Marcos, Lima, Peru, ⁵Hospital Nacional Guillermo Almenara Irigoyen; Universidad Nacional Mayor de San Marcos, La Molina, Peru, ⁶The University of Alabama at Birmingham, Oakland, CA, ⁷Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Peru; Hospital Guillermo Almenara Irigoyen, EsSalud, Lima, Peru, Lima, Peru, ⁸Universidad Científica del Sur, San Isidro, Peru
Background/Purpose: Depression and anxiety symptoms have been reported in 28% of patients suffering from vasculitides. However, in patients with ANCA-associated vasculitis (AAV), their frequency and…
Abstract Number: 0743 • ACR Convergence 2025
Giant Cell Arteritis Relapse After Treatment with Two Months of Prednisone and 12 Months of Tocilizumab
David O'Dea¹, Guy Katz¹, Belen Arevalo Molina¹, Adam Jarvie², Mark Matza¹, Ana Fernandes¹, John Stone³ and Sebastian H Unizony⁴, ¹Massachusetts General Hospital, Boston, MA, ²Emory University School of Medicine, Atlanta, GA, ³Massachusetts General Hospital , Harvard Medical School, Concord, MA, ⁴Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: The optimal duration of tocilizumab (TCZ) treatment for giant cell arteritis (GCA) is unclear. Observational studies have shown that 50-60% of patients relapse after…
Abstract Number: 0025 • ACR Convergence 2025
Expansion and Transcriptional Reprogramming of CD14⁺ and CD16⁺ Monocytes in Behçet’s Disease
Elio Carmona¹, Rabia Deniz², Cemal Bes³, Haner Direskeneli⁴, Ahmet Gul⁵ and Amr Sawalha⁶, ¹Division of Pediatric Rheumatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA, Pittsburgh, ²University of Health Sciences Basaksehir Çam and Sakura City Hospital, Istanbul, Turkey, ³University of Health Sciences, Basaksehir Çam and Sakura City Hospital, Istanbul, Turkey, ⁴Marmara University, ISTANBUL, Turkey, ⁵Istanbul University, Istanbul, Turkey, ⁶University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Behçet’s disease (BD) is a chronic, relapsing inflammatory disease characterized by complex immunopathogenesis and limited treatment options. Monocytes are known to play a significant…
Abstract Number: 2525 • ACR Convergence 2025
Point-of-Care Risk Factors for Systemic Disease in Patients Presenting with Small Vessel Vasculitis of the Skin
Arjun Mahajan¹, William Song², Andrew Walls³, Arash Mostaghimi³, Robert Micheletti² and Evan Piette³, ¹Harvard Medical School, Boston, ²Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ³Brigham and Women's Hospital, Harvard Medical School, Boston
Background/Purpose: Small vessel vasculitis (SVV) presenting in the skin may be skin-limited or a manifestation of systemic vasculitis or an underlying autoimmune disease. However, no…
Abstract Number: 1764 • ACR Convergence 2025
Development and Validation of a Simulation Model for Induction of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
Naomi Patel¹, Aaron Wu², Eli Miloslavsky³, Peter Merkel⁴, John Stone⁵, Hyon K. Choi⁶, Zachary Wallace³ and Emily Hyle², ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Boston, ³Massachusetts General Hospital, Newton, MA, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Massachusetts General Hospital , Harvard Medical School, Concord, MA, ⁶MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA
Background/Purpose: Evaluating the effectiveness and safety profile of treatment strategies for the induction of remission of individuals with newly diagnosed AAV is important for guiding…
Abstract Number: 1604 • ACR Convergence 2025
Impact and risk factors of anti-rituximab antibodies in small-vessel vasculitis: a multicenter retrospective study
Lucas Khellaf¹, Raphaele Seror², caterina ricordi³, stephanie chhun⁴, audes gleizes⁴, hervé lobbes⁵, clara pouchelon⁶, marie Charlotte Besse⁷, Jean-Emmanuel Kahn⁸, sabine revuz⁹, Marina Cumin¹⁰, Dimitri Titeca-Beauport¹¹, Matthias Papo⁶, Philippe Rémy⁶, marie Desprets¹², florian garo¹³, Charles Ronsin¹⁴, Salima Hacein-Bey-Abina⁶, Amélie Servettaz¹⁵, Cacoub Patrice¹⁶, Xavier Puéchal¹⁷ and Benjamin Terrier¹⁸, ¹AP-HP, Paris, ²Department of Rheumatology, National referral center for auto immune disease and Sjogren disease, Université Paris-Saclay, INSERM UMR¹¹⁸⁴: Centre for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Le Kremlin Bicêtre, Paris, France., le kremlin bicetre, France, ³Unit of Rheumatology, Azienda USL - IRCCS di Reggio Emilia, and University of Modena and Reggio Emilia, Reggio Emilia, Italy, ⁴APHP, Paris, Ile-de-France, France, ⁵Department of Internal Medicine, Hôpital Estaing, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France, ⁶APHP, Paris, France, ⁷CHU Tours, Tours, France, ⁸Ambroise Paré hospital, Boulogne, France, ⁹CHU de la Réunion, Réunion, France, ¹⁰Centre hospitalier de Libourne, Libourne, France, ¹¹CHU Amiens, Amiens, France, ¹²CH Chôlet, Cholet, France, ¹³CHU Nîmes, Nîmes, France, ¹⁴CHU Nantes, Nantes, France, ¹⁵Internal Medicine, CHU Reims, Reims, France, ¹⁶Department of Internal Medicine and Clinical Immunology, Sorbonne Universités, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Centre national de références Maladies Autoimmunes et systémiques rares, Centre national de références Maladies Autoinflammatoires rares et Amylose inflammatoire (CEREMAIA), INSERM, UMR S⁹⁵⁹, Immunology-Immunopathology-Immunotherapy (I³), Paris, France, Paris, France, ¹⁷Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, and Université Paris Cité, Paris ( ⁷⁵⁰¹⁴ ), Ile-de-France, France, ¹⁸Cochin Hospital, Paris, France
Background/Purpose: Small vessel vasculitis mainly includes ANCA-associated vasculitis (AAV) and cryoglobulinemic vasculitis (CV), leading to significant organ damage. Rituximab (RTX), an anti-CD20 monoclonal antibody, has…
Abstract Number: 0713 • ACR Convergence 2025
Differentiating Primary Anti-Neutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis from Secondary Forms
Adil Vural¹, Chao Zhang², Yaseen Kinanah¹, Cassandra Calabrese³ and Adam Brown⁴, ¹Cleveland Clinic, Cleveland, OH, ²Cleveland Clinic, Cleveland Heights, OH, ³Cleveland Clinic Foundation, Cleveland Heights, OH, ⁴Cleveland Clinic, Shaker Heights, OH
Background/Purpose: ANCA associated vasculitis (AAV) is a severe autoimmune disorder with substantial morbidity and mortality. Establishing the diagnosis might be challenging due to the existence…
Abstract Number: 0740 • ACR Convergence 2025
Intravenous versus subcutaneous administration of Tocilizumab in aortitis associated with giant cell arteritis: multicenter open-label study of 196 patients
Carmen Secada-Gómez¹, Javier Loricera², Adrian Martin-Gutierrez³, Santos Castañeda⁴ and Ricardo Blanco¹, ¹Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ³Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Renedo de Piélagos, Spain, ⁴Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain
Background/Purpose: Aortitis associated to Giant cell arteritis (GCA) (GCA-aortitis) is one of the most severe manifestation of GCA. Tocilizumab (TCZ) has demonstrated efficacy in large-vessel…
Abstract Number: 2521 • ACR Convergence 2025
DANGER Score as Predictor of Mortality in ANCA-Associated Vasculitis with or without Glomerulonephritis: Data from the Almenara Vasculitis Cohort
Victor Pimentel-Quiroz¹, Alvaro Oyarce-Calderón², Allison Figueroa-Sánchez³, Leonor León-Yaurimucha³, Rocío Gamboa-Cárdenas⁴, Zoila Rodríguez-Bellido⁵, Risto Perich-Campos⁶, Graciela Alarcón⁷ and Manuel Ugarte-Gil⁸, ¹Universidad Científica del Sur, San Isidro, Peru, ²Hospital Nacional Guillermo Almenara Irigoyen, San Miguel, Peru, ³Universidad Científica del Sur, Lima, Peru, ⁴Universidad Científica del Sur, Lima, Peru, ⁵Hospital Nacional Guillermo Almenara Irigoyen; Universidad Nacional Mayor de San Marcos, Lima, Peru, ⁶Hospital Nacional Guillermo Almenara Irigoyen; Universidad Nacional Mayor de San Marcos, La Molina, Peru, ⁷The University of Alabama at Birmingham, Oakland, CA, ⁸Universidad Cientifica del Sur, Lima, Peru
Background/Purpose: The DANGER score can predict mortality in patients with ANCA-associated vasculitis (AAV) with glomerulonephritis (GN). However, this score has not been widely validated and,…
Abstract Number: 1632 • ACR Convergence 2025
PET/CT-Based Distribution of Arterial Involvement and Its Association With Clinical Outcomes in Takayasu Arteritis
Tokio Katakura¹, Tsuyoshi Shirai², Kentaro Mori¹, Mikihiro Takahashi¹, Yuito Tanno³, Soshi Okazaki³, So Itoi³, Yosuke Hoshi³, Tomoaki Machiyama³, Yusho Ishii³, Hiroko Sato³ and Hiroshi Fujii³, ¹Department of Rheumatology, Tohoku University Hospital, Sendai, Japan, ²Department of Rheumatology, Tohoku University Hospital, Sendai, Miyagi, Japan, ³Department of Rheumatology, Tohoku University Hospital, Sendai

Background/Purpose: PET/CT enables assessment of active vascular inflammation in Takayasu arteritis (TAK), which is often difficult to evaluate with conventional imaging. Although the distribution of…
Abstract Number: 1597 • ACR Convergence 2025
Effectiveness and Safety of Rituximab Biosimilars in Small Vessel Vasculitis: a Systematic Literature Review
Caitlyn Kanters¹, Joo Young Lee², Christian Pagnoux³, Lillian Barra⁴, Jean-Paul Makhzoum⁵ and Arielle Mendel⁶, ¹McGill University, Montreal, Canada, ²Research institute of the McGill University Health Center, Montreal, QC, Canada, ³Mount Sinai Hospital, University Health Network, Toronto, and Canadian Vasculitis Research Network (CanVasc), Toronto, ON, Canada, ⁴Western University, London, ON, Canada, ⁵University of Montreal, Montreal, ⁶McGill University Health Centre, Montreal, Canada
Background/Purpose: To evaluate the safety and effectiveness of rituximab biosimilars in the treatment of small vessel vasculitis.Methods: The Medline, CINAHL, Cochrane, Embase and Web of…
Abstract Number: 0892 • ACR Convergence 2025
Relapse and Immune Dysregulation in Giant Cell Arteritis Are Linked to Mosaic Loss of the Y Chromosome
Simon M. Petzinna, Sophie-Marie Kirch, Maike S. Adamson, De Xi, Claus-Jürgen Bauer, Lena Kreis, Pantelis Karakostas, Rayk Behrendt, Sebastian Zimmer, Raul N. Jamin and Valentin S. Schäfer, University Hospital Bonn, Bonn, Nordrhein-Westfalen, Germany
Background/Purpose: Mosaic loss of the Y chromosome (mLOY) is the most common acquired somatic mutation. Epidemiological studies have linked mLOY to malignancies, as well as…

« Previous Page
1
…
3
4
5
6
7
…
41
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].